View Alert

Originator: CMO Messaging

From: CMO Messaging

Issue date: 03-Sep-2020 10:12:59

This alert has been issued to:
  • NHS Foundation Trusts (England) - Medical Director
  • NHS Foundation Trusts (England) - Chief Executive
  • NHS Trusts (England) - Medical Director
  • NHS Trusts (England) - Chief Executive

  • MHRA (Medicines) Drug Alerts (Various Recipients)
  • Other contacts
  • Independent Healthcare Providers (registered with CAS)
  • Clinical Commissioning Groups
  • NHS Regional Offices
  • Special Health Authorities
  • CMO Urgent Messages - Non-NHS Recipients on Public Health Link
  • MHRA (Medicines) Drug Alerts - Non-NHS Recipients
  • Territorial CMOs in Northern Ireland, Scotland & Wales
  • Regional Directors of Public Health
  • Consultants in Communicable Diseases
  • CMO Urgent Messages - Recipients on Public Health Link
  • Director of Public Health
  • DHSC Supply Disruption - Medicines

Action category: Important information for immediate action

Title: Update: publication of an interim clinical commissioning policy: Remdesivir for patients hospitalised with COVID-19 (adults and children aged 12 years and older)

Broadcast content:
This alert replaces the most recent Remdesivir alert CEM/CMO/2020/028 which was issued on 03 July. 

The alert has been updated (on page 2) to reflect the publication of revised World Health Organisation (WHO) guidance on the use of corticosteroids in the treatment of COVID-19.

Earlier today we issued an alert on this updated guidance, and have now updated this Remdesivir alert accordingly.

Additional information: This alert does not need to be cascaded to primary care.

Alert reference: CEM/CMO/2020/028(U)


Contact our helpdesk


Medicines and Healthcare products Regulatory Agency